Focal solid splenic lesions, benign or malignant, are often
|
|
- Aubrie Taylor
- 6 years ago
- Views:
Transcription
1 The Role of F-FDG PET/CT in the Evaluation of Solid Splenic Masses Ur Metser, MD, and Einat Even-Sapir, MD, PhD F-Fluorodeoxyglucose positron emission tomography/computed tomography is a noninvasive imaging modality that appears to have a high negative-predictive value for malignancy in assessing solid splenic masses discovered on conventional imaging modalities. Histological sampling is recommended for fluorodeoxyglucose-avid splenic masses, as the main differential diagnosis includes malignancy, either primary or secondary, or granulomatous disease. Semin Ultrasound CT MRI 27: Elsevier Inc. All rights reserved. Department of Nuclear Medicine, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. Address reprints requests to: Ur Metser, MD, Department of Nuclear Medicine, Tel-Aviv Sourasky Medical Center, 6 Weizman Street, Tel-Aviv, Israel. umetser@tasmc.health.gov.il Focal solid splenic lesions, benign or malignant, are often discovered incidentally. The most common benign entities are hemangioma, granuloma, and hamartoma. Focal infarct and abscess may also occasionally appear as solid masses on imaging. Sporadically, rarer entities such as littoral cell angioma, inflammatory pseudotumor, or Gaucher nodules have been reported. 1-5 The most frequent malignancies to involve the spleen are lymphoma, leukemic infiltrates, metastases (most commonly from lung, breast, gastrointestinal cancers, or melanoma), or rarely, primary angiosarcoma of the spleen. 6-8 The morphological imaging characteristics of solid splenic masses have been described for most conventional imaging modalities. Hypovascular masses in an enlarged spleen and generalized lymphadenopathy may be suggestive of lymphoma. A hypervascular splenic mass, with metastatic disease, may be suggestive of primary angiosarcoma of the spleen. 9 When abnormalities exist in the spleen as well as in other organs, histological sampling is usually performed from nonsplenic sites, to avoid iatrogenic injury to the spleen. However, in most cases making a definitive diagnosis based on imaging alone is difficult, especially if no other abnormalities exist. Splenic fine-needle biopsies are being performed with increasing frequency in recent years with a high success rate ranging from 63 to 91% 10,11 and a complication rate ranging from 1.5 to 13%. 10,12 Major hemorrhage secondary to splenic biopsy has been reported not infrequently (7.7% in one series), requiring emergent splenectomy. Major bleeding is usually a result of biopsy from vascular lesions such as littoral cell angioma or angiosarcoma. 10 Therefore, judicious use of splenic needle biopsies appears prudent. In recent years, F-fluorodeoxyglucose ( F-FDG) positron emission tomography (PET) imaging has evolved as a powerful noninvasive imaging modality, mostly for oncology, but also in nononcological indications, such as assessment of fever of unknown origin. 13 In-line, hybrid PET/CT scanners have been introduced into routine clinical use in the past several years, enabling metabolic assessment of anatomical abnormalities. The purpose of this review was to describe the potential role of F-FDG PET/computed tomography (CT) in the evaluation of solid splenic lesions. Positron Emission Tomography Basic Principles PET imaging is based on the use of a biochemical molecule labeled with a positron-emitter (such as F, 11 C, 15 O) enabling in vivo tracking of the radioactive compound. During the decay process of the radioisotope, a positron is emitted, which after traveling a short distance (about a millimeter) encounters an electron from surrounding molecules. The two particles annihilate each other, resulting in emission of two -rays of 511 kev at 0 degrees to one another (Fig 1). When detected simultaneously (within 12 nanoseconds) by two opposed detectors, it is assumed that they both originated from the same annihilation event located along a line connecting the two detectors. Data collected are reconstructed into an image using standard algorithms. Attenuation correction is performed traditionally by calculating the ratio between two additional scans, a blank scan and a transmission scan, performed with an external positron-emitting /06/$-see front matter 2006 Elsevier Inc. All rights reserved. doi: /j.sult
2 Role of F-FDG PET/CT in the evaluation of solid splenic masses 421 Figure 1 Positron (marked ) encounters an electron (marked ). Annihilation process results in emission of two opposite -rays of 511 kev. Gamma rays are detected by detectors ( D ) of PET scanner. rotating 68 Germanium rod source. 14 With PET/CT scanners, attenuating correction is performed with a fraction of the time using CT data, thus obviating the need for a transmission scan, reducing acquisition time and improving patient throughput. 15 PET/CT The paucity of anatomical data from F-FDG-PET scans hampers lesion localization and thus interpretation of focal uptake of F-FDG. Focal uptake may be physiological or may indicate significant pathology. For example, focal uptake along the chest wall may be due to physiological uptake in intercostal muscles or may be due to a malignant pleural plaque. In-line hybrid PET and CT scanners have been in clinical use for several years. 16 Several studies have been published on the advantages of fusion imaging, showing better lesion localization, more accurate characterization of lesions as benign or malignant, and better diagnostic accuracy as compared to side-by-side reading of PET and CT. 17, F-Fluorodeoxyglucose F-FDG is the most common radiotracer used for PET imaging. Much like glucose, it is transported into cells by glucose transporter proteins and is phosphorylated by hexokinase to F-FDG-6-phosphatase. However, since F-FDG-6- phosphatase does not enter subsequent glucose metabolic pathways and since its permeability in membranes is low, it is effectively trapped within cells. The normal biodistribution of F-FDG is the brain, with variable uptake in the myocardium, and gastrointestinal tract. The kidneys excrete F- FDG and therefore F-FDG is normally seen along the genitourinary tract. Physiological uptake in the liver and spleen is generally uniformly low. 19 Many types of tumors exhibit overexpression of transporter proteins, high levels of hexokinase, and decreased levels of glucose-6-phosphatase. Therefore, these cells show increased uptake of F-FDG, providing the basis for oncology imaging using F-FDG-PET. It should however be borne in mind that F-FDG is not tumor-specific and increased Figure 2 Splenic infarct simulating mass lesion (CT, left; PET, middle; fused PET/CT, right). A subtle hypodense lesion is seen in posterior aspect of spleen on CT. PET and fused PET/CT images show lesion to be photopenic (arrow), consistent with an infarct. (Color version of figure is available online.)
3 422 U. Metser and E. Even-Sapir Figure 3 Sarcoidosis. Axial PET/CT images (CT, left; PET, middle; fused PET/CT, right). (A) Symmetrical abnormal uptake of FDG is seen in small hilar and mediastinal lymph nodes. (B) Multiple small FDG-avid nodules are seen in the splenic parenchyma. (Color version of figure is available online.) F-FDG uptake may be seen in a variety of benign conditions including inflammation. 20 F-FDG-PET/CT in Solid Splenic Masses Benign Solid Splenic Masses Most benign solid splenic masses such as hemangiomas or hamartomas of the spleen are not expected to show abnormal uptake of F-FDG. Focal infarcts which may on occasion appear mass-like are photopenic on F-FDG-PET (Fig 2). However, some benign lesions exhibit abnormal uptake of F-FDG, most commonly splenic abscess and active granulomatous diseases involving the spleen. Activated leukocytes, especially monocytes, show increased glucose uptake due to elevated levels of glucose transporter proteins. Furthermore, cytokines and growth factors increase the affinity of these transporters to glucose. 21,22 Granulomatous disease involving the spleen may be infectious (eg, tuberculosis, Brucella) or inflammatory (eg, sarcoidosis). In routine clinical practice, granulomatous disease may be suggested prospectively on whole-body imaging due to multisite involvement and typical imaging patterns (Fig 3). Activated macrophages may also be the mechanism for increased uptake of FDG in inflammatory pseudotumor of the spleen. Inflammatory pseudotumor is a benign, yet potentially locally aggressive lesion. Although its etiology is unknown, several factors have been implicated including infection and autoimmune processes. 23 It may mimic malignancy on both conventional imaging (sonography, CT, and MRI) and F-FDG-PET (Fig 4). Gaucher disease is a rare hereditary lysosomal storage disorder with accumulation of glucocerebroside in reticuloendothelial cells throughout the body, resulting in hepatosplenomegaly. Splenic infarcts and focal splenic nodules representing clusters of macrophage-like cells (termed Gaucher cells ) can be found in approximately a third of patients with type I disease on magnetic resonance (MR), likely an Figure 4 Inflammatory pseudotumor of spleen. Axial PET/CT images (CT, left; PET, middle; fused PET/CT, right): a 3.5-cm FDG-avid solid splenic mass indistinguishable from malignancy. Surgical pathology showed histological features and immunostains consistent with an inflammatory pseudotumor of the spleen. (Color version of figure is available online.)
4 Role of F-FDG PET/CT in the evaluation of solid splenic masses 423 Figure 5 Gaucher nodule in spleen. (A) MIP PET image: moderate focal FDG uptake (arrows) with an SUV of 4.2 in an enlarged spleen measuring16.5 cm in length. (B) Axial PET/CT images (CT, left; PET, middle; fused PET/CT, right) shows uptake in a 2.3-cm hypodense splenic mass. (Color version of figure is available online.) underestimate of their true frequency on pathology. 24 No studies have been performed to date on F-FDG-PET and Gaucher nodules in the spleen. Although expression of proinflammatory mediators is not always apparent on Gaucher cells, markers characteristic of alternatively activated macrophages are found. 25 Therefore, Gaucher nodules may potentially be FDG-avid (Fig 5). Splenic Metastases Metastases in the spleen are uncommon, usually occurring as part of disseminated metastatic disease. 26 In postmortem examination of cancer patients the prevalence of splenic metastases was between 2.3 and 12.9%, most commonly from carcinoma of lung, breast, ovary, and melanoma. 26,27 Statistically, most solitary splenic lesions in cancer patients are benign, as solitary splenic metastases are rare. 28 Nonetheless, solitary or multiple splenic masses warrant further evaluation and specific characterization to rule out malignancy, even when other metastatic disease is documented, as in some clinical settings they may alter patient management (Fig 6). A metabolically active splenic mass in a patient with known FDG-avid malignancy would likely represent a malignant splenic deposit. Conversely, lack of F-FDG uptake in a splenic mass would indicate a lesion that is not related to the patient s known FDG-avid malignant disease and therefore would likely be benign. In a recent study performed on 68 oncology patients with FDG-avid malignancy and solid splenic masses on anatomical imaging, F-FDG-PET/CT had 100% accuracy in characterizing lesions as benign or malignant. In 20 additional patients without previously diagnosed malignancy and a solid splenic mass, lack of uptake of F- FDG-PET also had a 100% negative-predictive value for malignancy. 29 It should however be kept in mind that non-fdgavid tumors, such as some renal or thyroid cancers, may metastasize to the spleen. Therefore, when encountering a non-fdg-avid splenic mass, the CT portion of the PET/CT study should be meticulously assessed for potential non- FDG-avid malignancy. Primary Malignancies of the Spleen The spleen is a frequent site of involvement in patients with non-hodgkin s lymphoma and may be involved in one-third of patients with Hodgkin s disease. 24 On imaging, lymphomatous involvement of the spleen may manifest as either focal lesions or diffuse infiltration. A solid splenic mass may occasionally be the presenting sign of disseminated lymphoma (Fig 7). Recent reports have shown that F-FDG-PET is more accurate than CT and 67 Ga-citrate scintigraphy for identifying splenic involvement by lymphoma. 30,31 Primary malignant lymphoma of the spleen is defined as lymphoma involving the spleen with or without lymph nodes in the splenic hilum. 32 Primary malignant lymphoma of the spleen is uncommon, yet it is the most common primary malignancy of the spleen. Primary nonhematopoietic tumors of the spleen may be epithelial in origin (namely, angiosarcoma and hemangioendothelioma) or from connective tissue (such as fibrosarcoma). Of these extremely rare entities, angiosarcoma is the most common tumor to involve the spleen with fewer than 200 cases reported in the literature. 33 Clinically, these tumors
5 U. Metser and E. Even-Sapir 424 Figure 6 Solitary splenic metastasis in 60-year-old patient with sigmoid cancer. (A) Axial PET/CT images (CT, left; PET, middle; fused PET/CT, right): an FDG-avid mass in the sigmoid colon (arrows). (B) Axial PET/CT images (CT, left; PET, middle; fused PET/CT, right): an FDG-avid metastatic deposit in the spleen (arrow). (Color version of figure is available online.) may manifest with left upper quadrant abdominal pain, anemia, coagulopathy, and spontaneous rupture. Hematogenous metastases at diagnosis are common and overall prognosis is poor.34 Although there are no reports of F-FDGPET in the diagnosis of primary splenic angiosarcoma, angiosarcoma of the pleura and chest wall has been shown to be FDG-avid.35 Conclusion Conventional imaging modalities (sonography, CT, and MRI) often discover incidental solid splenic masses. Frequently, these are difficult to definitively characterize on conventional imaging, as even hemangiomas, the most common solid lesion in the spleen, may have a complex appearance, Figure 7 Diffuse large cell lymphoma. A 58-year-old woman sent for FDG-PET/CT due to solid splenic masses discovered incidentally on abdominal CT. Axial PET/CT images (CT, left; PET, middle; fused PET/CT, right). (A) Multiple FDG-avid solid splenic masses (arrows). (B) FDG-avid axillary nodes (not shown) and groin node (arrow). Excisional biopsy of groin node showed diffuse large cell lymphoma. (Color version of figure is available online.)
6 Role of F-FDG PET/CT in the evaluation of solid splenic masses 425 making differentiation from malignancy difficult. Splenic biopsy, although feasible, is associated with morbidity, especially for vascular lesions. F-FDG-PET/CT is a noninvasive imaging modality that appears to have a high negative-predictive value for malignancy in assessing solid splenic masses. The main differential diagnosis for FDG-avid splenic lesions is malignancy (primary or secondary), or granulomatous disease. Therefore, histological sampling is warranted for FDGavid splenic masses. References 1. Rabushka LS, Kawashima A, Fishman EK: Imaging of the spleen: CT with supplemental MR examination. Radiographics 14: , Ramani M, Reinhold C, Semelka RC, et al: Splenic hemangiomas and hamartomas: MR imaging characteristics of 28 lesions. Radiology 202: , Levy AD, Abbott RM, Abbondanzo SL: Littoral cell angioma of the spleen: CT features with clinicopathologic comparison. Radiology 230: , Variami E, Terpos E, Vgenopoulou S, et al: Inflammatory pseudotumor of the spleen: a case report and review of the literature. Ann Hematol 78: , Terk MR, Esplin J, Lee K, et al: MR imaging of patients with type 1 Gaucher s disease: relationship between bone and visceral changes. AJR Am J Roentgenol 165: , Bragg DG, Colby TV, Ward JH: New concepts in the non-hodgkin lymphoma: radiologic implications. Radiology 159: , Lee SS, Morgenstern L, Phillips EH, et al: Splenectomy for splenic metastases: a changing clinical spectrum. Am Surg 66: , Paterson A, Frush DP, Donnelly LF, et al: A pattern-oriented approach to splenic imaging in infants and children. Radiographics 19: , Thompson WM, Levy AD, Aguilera NS, et al: Angiosarcoma of the spleen: imaging characteristics in 12 patients. Radiology 235: , Keogan MT, Freed KS, Paulson EK, et al: Imaging-guided percutaneous biopsy of focal splenic lesions: update on safety and effectiveness. AJR Am J Roentgenol 172: , Venkataramu NK, Gupta S, Sood BP, et al: Ultrasound guided fine needle aspiration biopsy of splenic lesions. Br J Radiol 72: , Lindgren PG, Hagberg H, Eriksson B, et al: Excision biopsy of the spleen by ultrasound guidance. Br J Radiol 58: , Bleeker-Rovers CP, de Kleijn EM, Corstens FH, et al: Clinical value of FDG PET in patients with fever of unknown origin and patients suspected of focal infection or inflammation. Eur J Nucl Med Mol Imag 31:29-37, Maisey MM, Wahl RL, Barrington SF: Principles and Methods, in Marsden PK (ed): Atlas of Clinical Positron Emission Tomography. London, UK, Arnold, 1999, pp Messa C, Bettinardi V, Picchio M, et al: PET/CT in diagnostic oncology. Q J Nucl Med Mol Imag 48:66-75, Beyer T, Townsend DW, Brun T, et al: A combined PET/CT scanner for clinical oncology. J Nucl Med 41: , Antoch G, Saoudi N, Kuehl H, et al: Accuracy of whole-body dualmodality fluorine--2-fluoro-2-deoxy-d-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 22: , Metser U, Golan O, Levine CD, et al: Tumor lesion detection: when is integrated positron emission tomography/computed tomography more accurate than side-by-side interpretation of positron emission tomography and computed tomography? J Comput Assist Tomogr 29: , Gallagher BM, Ansari A, Atkins H, et al: Radiopharmaceuticals XXVII: F-labeled 2-deoxy-2-fluoro-D-glucose as a radiopharmaceutical for measuring regional myocardial glucose metabolism in vivo tissue distribution and imaging studies in animals, J Nucl Med : , Love C, Tomas MB, Tronco GG, et al: FDG PET of infection and inflammation. Radiographics 25: , Zhuang H, Alavi A: -fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 32:47-59, Paik JY, Lee KH, Choe YS, et al: Augmented F-FDG uptake in activated monocytes occurs during the priming process and involves tyrosine kinases and protein kinase C. J Nucl Med 45: , Scott L, Blair G, Taylor G, et al: Inflammatory pseudotumors in children. J Pediatr Surg 23: , Hill SC, Damaska BM, Ling A, et al: Gaucher disease: abdominal MR imaging findings in 46 patients. Radiology 4: , Jmoudiak M, Futerman AH: Gaucher disease: pathological mechanisms and modern management. Br J Haematol 129:178-8, Berge T: Splenic metastases. Frequencies and patterns. Acta Pathol Microbiol Scand 82: , Morgenstern L, Rosenberg J, Geller SA: Tumors of the spleen. World J Surg 9: , Agha-Mohammadi S, Calne RY: Solitary splenic metastasis: case report and review of the literature. Am J Clin Oncol 24: , Metser U, Miller E, Kessler A, et al: Solid splenic masses: evaluation with F-FDG PET/CT. J Nucl Med 46:52-59, Rini JN, Leonidas JC, Tomas MB, et al: F-FDG PET versus CT for evaluating the spleen during initial staging of lymphoma. J Nucl Med 44: , Kostakoglu L, Leonard JP, Kuji I, et al: Comparison of fluorine- fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer 94: , Brox A, Shustik C: Non-Hodgkin s lymphoma of the spleen. Leuk Lymphoma 11: , Smith VC, Eisenberg BL, McDonald EC: Primary splenic angiosarcoma. Case report and literature review. Cancer 55: , Autry JR, Weitzner S: Hemangiosarcoma of spleen with spontaneous rupture. Cancer 35: , Del Frate C, Mortele K, Zanardi R, et al: Pseudomesotheliomatous angiosarcoma of the chest wall and pleura. J Thorac Imag : , 2003
Although not as common as focal hepatic masses, solid
Solid Splenic Masses: Evaluation with F-FDG PET/CT Ur Metser, MD 1,2 ; Elka Miller, MD 2 ; Ada Kessler, MD 2 ; Hedva Lerman, MD 1 ; Gennady Lievshitz, MD 1 ; Ran Oren, MD 3 ; and Einat Even-Sapir, MD,
More informationLos Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010
Los Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010 Self Assessment Module on Nuclear Medicine and PET/CT Case Review FDG PET/CT IN LYMPHOMA AND MELANOMA Submitted
More informationPositron Emission Tomography in Lung Cancer
May 19, 2003 Positron Emission Tomography in Lung Cancer Andrew Wang, HMS III Patient DD 53 y/o gentleman presented with worsening dyspnea on exertion for the past two months 30 pack-year smoking Hx and
More informationPrinciples of nuclear metabolic imaging. Prof. Dr. Alex Maes AZ Groeninge Kortrijk and KULeuven Belgium
Principles of nuclear metabolic imaging Prof. Dr. Alex Maes AZ Groeninge Kortrijk and KULeuven Belgium I. Molecular imaging probes A. Introduction - Chemical disturbances will precede anatomical abnormalities
More informationDr Sneha Shah Tata Memorial Hospital, Mumbai.
Dr Sneha Shah Tata Memorial Hospital, Mumbai. Topics covered Lymphomas including Burkitts Pediatric solid tumors (non CNS) Musculoskeletal Ewings & osteosarcoma. Neuroblastomas Nasopharyngeal carcinomas
More informationFDG-PET/CT for cancer management
195 REVIEW FDG-PET/CT for cancer management Hideki Otsuka, Naomi Morita, Kyo Yamashita, and Hiromu Nishitani Department of Radiology, Institute of Health Biosciences, The University of Tokushima, Graduate
More informationPOSITRON EMISSION TOMOGRAPHY (PET)
Status Active Medical and Behavioral Health Policy Section: Radiology Policy Number: V-27 Effective Date: 08/27/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members should
More informationAn Introduction to PET Imaging in Oncology
January 2002 An Introduction to PET Imaging in Oncology Janet McLaren, Harvard Medical School Year III Basics of PET Principle of Physiologic Imaging: Allows in vivo visualization of structures by their
More informationIndex. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic
More informationMolecular Imaging and Cancer
Molecular Imaging and Cancer Cancer causes one in every four deaths in the United States, second only to heart disease. According to the U.S. Department of Health and Human Services, more than 512,000
More informationperformed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.
Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician
More informationVIII. 9. FDG-PET for Diagnosis of an Advanced Jejunal Adenocarcinoma with Distant Metastases, Compared with Gallium Scintigraphy
CYRIC Annual Report 2003 VIII. 9. FDG-PET for Diagnosis of an Advanced Jejunal Adenocarcinoma with Distant Metastases, Compared with Gallium Scintigraphy Yamaura G., Yoshioka T., Yamaguchi K. *, Fukuda
More informationPitfalls in Oncologic Diagnosis with PET CT. Nononcologic Hypermetabolic Findings
Pitfalls in Oncologic Diagnosis with PET CT. Nononcologic Hypermetabolic Findings Poster No.: C-1359 Congress: ECR 2012 Type: Educational Exhibit Authors: J. Rossi 1, C. A. Mariluis 1, E. Delgado 1, R.
More informationPET CT for Staging Lung Cancer
PET CT for Staging Lung Cancer Rohit Kochhar Consultant Radiologist Disclosures Neither I nor my immediate family members have financial relationships with commercial organizations that may have a direct
More informationFDG-PET Findings in an Ovarian Endometrioma: A Case Report
FDG-PET Findings in an Ovarian Endometrioma: A Case Report Jia-Huei Lin 1, Victor Chit-kheng Kok 2, Jian-Chiou Su 3 1 Department of Nuclear medicine, Kuang Tien General Hospital, Sha-Lu, Taichung, Taiwan
More informationThe Use of PET Scanning in Urologic Oncology
The Use of PET Scanning in Urologic Oncology Dr Nicholas C. Buchan Uro-oncology Fellow 1 2 Aims To understand the basic concepts underlying PET scanning. Understand the emerging role of PET Scanning for
More informationPET/CT Frequently Asked Questions
PET/CT Frequently Asked Questions General Q: Is FDG PET specific for cancer? A: No, it is a marker of metabolism. In general, any disease that causes increased metabolism can result in increased FDG uptake
More informationThe Role of PET / CT in Lung Cancer Staging
July 2004 The Role of PET / CT in Lung Cancer Staging Vlad Vinarsky, Harvard Medical School Year IV Patient AM HPI: 81 yo F p/w hemoptysis x 1 month LLL lesion on CXR, not responsive to Abx 35 pack-year
More informationResearch Article Prevalence of Clinically Significant Extraosseous Findings on Unenhanced CT Portions of 18 F-Fluoride PET/CT Bone Scans
The Scientific World Journal Volume 2012, Article ID 979867, 5 pages doi:10.1100/2012/979867 The cientificworldjournal Research Article Prevalence of Clinically Significant Extraosseous Findings on Unenhanced
More informationProf. Dr. NAGUI M. ABDELWAHAB,M.D.; MARYSE Y. AWADALLAH, M.D. AYA M. BASSAM, Ms.C.
Role of Whole-body Diffusion MR in Detection of Metastatic lesions Prof. Dr. NAGUI M. ABDELWAHAB,M.D.; MARYSE Y. AWADALLAH, M.D. AYA M. BASSAM, Ms.C. Cancer is a potentially life-threatening disease,
More informationTesticular relapse of non-hodgkin Lymphoma noted on FDG-PET
Testicular relapse of non-hodgkin Lymphoma noted on FDG-PET Stephen D. Scotti 1*, Jennifer Laudadio 2 1. Department of Radiology, North Carolina Baptist Hospital, Winston-Salem, NC, USA 2. Department of
More informationAppendix 1: Regional Lymph Node Stations for Staging Esophageal Cancer
Appendix 1: Regional Lymph Node Stations for Staging Esophageal Cancer Locoregional (N stage) disease was redefined in the seventh edition of the AJCC Cancer Staging Manual as any periesophageal lymph
More informationobjectives Pitfalls and Pearls in PET/CT imaging Kevin Robinson, DO Assistant Professor Department of Radiology Michigan State University
objectives Pitfalls and Pearls in PET/CT imaging Kevin Robinson, DO Assistant Professor Department of Radiology Michigan State University To determine the regions of physiologic activity To understand
More informationCOMENIUS-Project: SM&CLIL Radiation & Medicine
Medical imaging refers to the techniques and processes used to create images of the human body (or parts thereof) for clinical purposes. Thanks to modern mathematics and computer technology, medical imaging
More informationSclerosing angiomatoid nodular transformation (SANT) of the spleen: a case report with FDG-PET findings and literature review
Case Report Sclerosing angiomatoid nodular transformation (SANT) of the spleen: a case report with FDG-PET findings and literature review Acta Radiologica Open 5(8) 1 6! The Foundation Acta Radiologica
More informationImaging of Pulmonary Tuberculosis with 18 F-Fluoro-Deoxy-Glucose and
Send Orders for Reprints to reprints@benthamscience.net The Open Nuclear Medicine Journal, 2014, 6, 17-21 17 Open Access Imaging of Pulmonary Tuberculosis with 18 F-Fluoro-Deoxy-Glucose and 18 F-Ethylcholine
More information1 Introduction. 2 Materials and methods. LI Na 1 LI Yaming 1,* YANG Chunming 2 LI Xuena 1 YIN Yafu 1 ZHOU Jiumao 1
Nuclear Science and Techniques 20 (2009) 354 358 18 F-FDG PET/CT in diagnosis of skeletal metastases LI Na 1 LI Yaming 1,* YANG Chunming 2 LI Xuena 1 YIN Yafu 1 ZHOU Jiumao 1 1 Department of Nuclear Medicine,
More informationNuclear Medicine and PET. D. J. McMahon rev cewood
Nuclear Medicine and PET D. J. McMahon 150504 rev cewood 2018-02-15 Key Points Nuclear Medicine and PET: Imaging: Understand how Nuc Med & PET differ from Radiography & CT by the source of radiation. Be
More informationImaging Features of Sarcoidosis on MDCT, FDG PET, and PET/CT
AJR Integrative Imaging LIFELONG LEARNING FOR RADIOLOGY Imaging Features of Sarcoidosis on MDCT, FDG PET, and PET/CT Hima B. Prabhakar 1, Chad B. Rabinowitz 1, Fiona K. Gibbons 2, Walter J. O Donnell 2,
More informationFDG-PET value in deep endometriosis
Gynecol Surg (2011) 8:305 309 DOI 10.1007/s10397-010-0652-6 ORIGINAL ARTICLE FDG-PET value in deep endometriosis A. Setubal & S. Maia & C. Lowenthal & Z. Sidiropoulou Received: 3 December 2010 / Accepted:
More informationPleural effusion in patients with extrapleural primary malignancies
ORIGINAL ARTICLE Differentiation Between Malignant and Benign Pleural Effusion in Patients With Extra-Pleural Primary Malignancies Assessment With Positron Emission Tomography-Computed Tomography Jacob
More informationNuclear Medicine in Thyroid Cancer. Phillip J. Koo, MD Division Chief of Diagnostic Imaging
Nuclear Medicine in Thyroid Cancer Phillip J. Koo, MD Division Chief of Diagnostic Imaging Financial Disclosures Bayer Janssen Learning Objectives To learn the advantages and disadvantages of SPECT/CT
More informationPositron emission tomography computed tomography
Interpretation and Reporting of Positron Emission Tomography Computed Tomographic Scans Harry Agress, Jr, MD,* Terence Z. Wong, MD, PhD, and Paul Shreve, MD Body oncology positron emission tomography computed
More informationBone and CT Scans Are Complementary for Diagnoses of Bone Metastases in Breast Cancer When PET Scans Findings Are Equivocal: A Case Report
Bone and CT Scans Are Complementary for Diagnoses of Bone Metastases in Breast Cancer When Scans Findings Are Equivocal: A Case Report Yuk-Wah Tsang 1, Jyh-Gang Leu 2, Yen-Kung Chen 3, Kwan-Hwa Chi 1,4
More informationSubject: PET Scan With or Without CT Attenuation. Original Effective Date: 11/7/2017. Policy Number: MCR: 610. Revision Date(s): Review Date:
Subject: PET Scan With or Without CT Attenuation Policy Number: MCR: 610 Revision Date(s): MHW Original Effective Date: 11/7/2017 Review Date: DISCLAIMER This Molina Clinical Review (MCR) is intended to
More informationImaging in gastric cancer
Imaging in gastric cancer Gastric cancer remains a deadly disease because of late diagnosis. Adenocarcinoma represents 90% of malignant tumors. Diagnosis is based on endoscopic examination with biopsies.
More informationNew Visions in PET: Surgical Decision Making and PET/CT
New Visions in PET: Surgical Decision Making and PET/CT Stanley J. Goldsmith, MD Director, Nuclear Medicine Professor, Radiology & Medicine New York Presbyterian Hospital- Weill Cornell Medical Center
More informationEvaluation and Management of Thyroid Nodules. Nick Vernetti, MD, FACE Palm Medical Group Las Vegas, Nevada
Evaluation and Management of Thyroid Nodules Nick Vernetti, MD, FACE Palm Medical Group Las Vegas, Nevada Disclosure Consulting Amgen Speaking Amgen Objectives Understand the significance of incidental
More informationCigna - Prior Authorization Procedure List: Radiology & Cardiology
Cigna - Prior Authorization Procedure List: Radiology & Cardiology Category CPT Code CPT Code Description 93451 Right heart catheterization 93452 Left heart catheterization 93453 Combined right and left
More informationDiagnostic challenge: Sclerosing Hemangioma of the Lung. Department of Medicine, Division of Pulmonary and Critical Care, Lincoln Medical and
Diagnostic challenge: Sclerosing Hemangioma of the Lung. S. Arias M.D, R. Loganathan M.D, FCCP Department of Medicine, Division of Pulmonary and Critical Care, Lincoln Medical and Mental Health Center/Weill
More informationPET/CT in lung cancer
PET/CT in lung cancer Andrei Šamarin North Estonia Medical Centre 3 rd Baltic Congress of Radiology 08.10.2010 Imaging in lung cancer Why do we need PET/CT? CT is routine imaging modality for staging of
More informationPulmonary Sarcoidosis - Radiological Evaluation
Original Research Article Pulmonary Sarcoidosis - Radiological Evaluation Jayesh Shah 1, Darshan Shah 2*, C. Raychaudhuri 3 1 Associate Professor, 2 1 st Year Resident, 3 Professor and HOD Radiology Department,
More informationThe Proper Use of PET/CT in Tumoring Imaging
The Proper Use of PET/CT in Tumoring Imaging Mijin Yun, M.D. Jong Doo Lee, M.D. Department of Radiology / Division of Nuclear Medicine Yonsei University College of Medicine, Severance Hospital E mail :
More informationM etastatic disease influences patient management; Whole body PET/CT for initial staging of choroidal melanoma SCIENTIFIC REPORT
1270 SCIENTIFIC REPORT Whole body PET/CT for initial staging of choroidal P T Finger, M Kurli, S Reddy, L B Tena, A C Pavlick... Aim: To investigate the value of whole body positron emission tomography/computed
More informationUsing PET/CT in Prostate Cancer
Using PET/CT in Prostate Cancer Legal Disclaimer These materials were prepared in good faith by MITA as a service to the profession and are believed to be reliable based on current scientific literature.
More informationCancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC
Cancers of unknown primary : Knowing the unknown Prof. Ahmed Hossain Professor of Medicine SSMC Definition Cancers of unknown primary site (CUPs) Represent a heterogeneous group of metastatic tumours,
More informationPrecise evaluation of the patient with a suspected primary GENERAL THORACIC SURGERY
GENERAL THORACIC SURGERY POSITRON EMISSION TOMOGRAPHIC IMAGING WITH FLUORODEOXYGLUCOSE IS EFFICACIOUS IN EVALUATING MALIGNANT PULMONARY DISEASE Geoffrey M. Graeber, MD* Naresh C. Gupta, MD** Gordon F.
More informationSectional Anatomy Quiz II
Sectional Anatomy II Rashid Hashmi Rural Clinical School, University of New South Wales, Wagga Wagga, New South Wales, Australia A R T I C L E I N F O Article type: Article history: Received: 3 Aug 2017
More informationCase Discussion Splenic Abscess
Case Discussion Splenic Abscess Personal Data Gender: male Birth Date: 1928/Mar/06th Allergy: Mefenamic Smoking: 0.5 PPD for 55 years Alcohol: negative (?) 4 Months Ago Abdominal pain: epigastric area
More informationPositron Emission Tomography (PET) for Staging Low-Grade Non-Hodgkin s Lymphomas (NHL)
CANCER BIOTHERAPY & RADIOPHARMACEUTICALS Volume 16, Number 4, 2001 Mary Ann Liebert, Inc. Positron Emission Tomography (PET) for Staging Low-Grade Non-Hodgkin s Lymphomas (NHL) F. Najjar, R. Hustinx, G.
More informationThe Diagnostic Value of PET/CT in Breast Cancer Recurrence and Metastases
Original Paper, Oncology. The Diagnostic Value of PET/CT in Breast Cancer Recurrence and Metastases Taalab, Kh. 1 ; Abutaleb, AS 1 ; Moftah, SG 2 ; Abdel-Mutaleb, MG 2 and Abdl-Mawla, YA 2. 1 Military
More information1. OVERVIEW 2. RADIOPHARMACEUTICAL UTILIZED
1. OVERVIEW F-18 Fluorodeoxyglucose Injection is indicated for positron emission tomography (PET) imaging in the following settings: a) Oncology: For assessment of abnormal glucose metabolism to assist
More informationDoes PET/CT Have an Additional Value in Detection of Osteolytic Bone Metastases.
Egyptian J. Nucl. Med., Vol 2, No. 2, Dec. 2009 65 ONCOLOGY, Original Article Does PET/CT Have an Additional Value in Detection of Osteolytic Bone Metastases. R. Riad, M.D.*, M. Awad, M.D. **, E. Eldebawy,
More informationUnusual Osteoblastic Secondary Lesion as Predominant Metastatic Disease Spread in Two Cases of Uterine Leiomyosarcoma
49 Unusual Osteoblastic Secondary Lesion as Predominant Metastatic Disease Spread in Two Cases of Uterine Leiomyosarcoma Loredana Miglietta a Maria Angela Parodi b Luciano Canobbio b Luca Anselmi c a Medical
More informationManagement of Neck Metastasis from Unknown Primary
Management of Neck Metastasis from Unknown Primary.. Definition Histologic evidence of malignancy in the cervical lymph node (s) with no apparent primary site of original tumour Diagnosis after a thorough
More informationBreast Sarcoidosis Appearing as a Primary Manifestation of Sarcoidosis: A Case Report 1
Breast Sarcoidosis Appearing as a Primary Manifestation of Sarcoidosis: A Case Report 1 Hye-Jeong Lee, M.D., Eun-Kyung Kim, M.D., Min Jung Kim, M.D., Ki Keun Oh, M.D., Se Hoon Kim, M.D. 2 Breast sarcoidosis
More informationMetachronic solitary breast metastasis from renal cell carcinoma: case report
Metachronic solitary breast metastasis from renal cell carcinoma: case report Abstract We describe the case of a patient with solitary and metachronic breast metastasis, 3 years after nephrectomy for renal
More informationLung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09
Lung Cancer Imaging Terence Z. Wong, MD,PhD Department of Radiology Duke University Medical Center Durham, NC 9/9/09 Acknowledgements Edward F. Patz, Jr., MD Jenny Hoang, MD Ellen L. Jones, MD, PhD Lung
More informationMolecular Imaging and Breast Cancer
Molecular Imaging and Breast Cancer Breast cancer forms in tissues of the breast usually in the ducts, tubes that carry milk to the nipple, and lobules, the glands that make milk. It occurs in both men
More informationPET-CT findings in surgically transposed ovaries
The British Journal of Radiology, 79 (2006), 110 115 1,2,3 R ZISSIN, MD, 1 U METSER, MD, 1 H LERMAN, MD, 1 G LIEVSHITZ, MD, 4 T SAFRA, MD and 1,3 E EVEN-SAPIR, MD, PhD Department of 1 Nuclear Medicine
More informationpatients with urinary tract infection and distended bladder
J of Nuclear Medicine Technology, first published online December 23, 2014 as doi:10.2967/jnmt.114.148031 Interesting layering of excreted 18 F-FDG in the urinary bladder in patients with urinary tract
More informationDetection of Soft Tissue Tumors on Bone Scintigraphy: Report of Four Cases
Detection of Soft Tissue Tumors on Bone Scintigraphy: Report of Four Cases Fariba Akhzari 1 MD and Mahrokh Daemi MD 2 1 Nuclear Medicine Department, 2 General Surgery Department, Sina Hospital, Faculty
More informationWhole body F-18 sodium fluoride PET/CT in the detection of bone metastases in patients with known malignancies: A pictorial review
Whole body F-18 sodium fluoride PET/CT in the detection of bone metastases in patients with known malignancies: A pictorial review Poster No.: C-1196 Congress: ECR 2014 Type: Educational Exhibit Authors:
More informationF NaF PET/CT in the Evaluation of Skeletal Malignancy
F NaF PET/CT in the Evaluation of Skeletal Malignancy Andrei Iagaru, MD September 26, 2013 School of of Medicine Ø Introduction Ø F NaF PET/CT in Primary Bone Cancers Ø F NaF PET/CT in Bone Metastases
More informationRadiological Manifestations of Metastatic Melanoma
Radiological Manifestations of Metastatic Melanoma Lia Hojman, Universidad de Chile Year VII Our patient: Clinical Presentation A 24 year old male. Former smoker. 8 months ago, he suffered a burn in his
More informationRadiology Pathology Conference
Radiology Pathology Conference Sharlin Johnykutty,, MD, Cytopathology Fellow Sara Majewski, MD, Radiology Resident Friday, August 28, 2009 Presentation material is for education purposes only. All rights
More informationSeptember 2014 Imaging Case of the Month. Michael B. Gotway, MD. Department of Radiology Mayo Clinic Arizona Scottsdale, AZ
September 2014 Imaging Case of the Month Michael B. Gotway, MD Department of Radiology Mayo Clinic Arizona Scottsdale, AZ Clinical History: A 57-year-old non-smoking woman presented to her physician as
More informationInternational Journal of Current Medical Sciences- Vol. 6, Issue,, pp , June, 2016 A B S T R A C T
ISSN: 2320-8147 International Journal of Current Medical Sciences- Vol. 6, Issue,, pp. 122-126, June, 2016 COMPUTED TOMOGRAPHY IN HEPATIC METASTASES Ananthakumar P and Adaikkappan M., Available online
More informationPET IMAGING (POSITRON EMISSION TOMOGRAPY) FACT SHEET
Positron Emission Tomography (PET) When calling Anthem (1-800-533-1120) or using the Point of Care authorization system for a Health Service Review, the following clinical information may be needed to
More informationRegular PET Scanning Without CT. Christian Cohade and Richard L. Wahl
Applications of Positron Emission Tomography/Computed Tomography Image Fusion in Clinical Positron Emission Tomography Clinical Use, Interpretation Methods, Diagnostic Improvements Christian Cohade and
More informationF-2-fluoro-2-deoxyglucose uptake in or adjacent to blood vessel walls
15 REVIEW 18 F-2-fluoro-2-deoxyglucose uptake in or adjacent to blood vessel walls Yoichi Otomi 1, Hideki Otsuka 2, Kaori Terazawa 1, Hayato Nose 1,3, Michiko Kubo 1, Kazuhide Yoneda 1, Kaoru Kitsukawa
More informationMEASUREMENT OF EFFECT SOLID TUMOR EXAMPLES
MEASUREMENT OF EFFECT SOLID TUMOR EXAMPLES Although response is not the primary endpoint of this trial, subjects with measurable disease will be assessed by standard criteria. For the purposes of this
More informationA 64 y.o. man presents to the hospital with persistent cough and hemoptysis. Fernando Mut Montevideo - Uruguay
A 64 y.o. man presents to the hospital with persistent cough and hemoptysis Fernando Mut Montevideo - Uruguay Teaching case Bone # 1 A 64 y.o. man presents to the hospital with persistent cough and hemoptysis.
More informationGeneral Nuclear Medicine
General Nuclear Medicine What is General Nuclear Medicine? What are some common uses of the procedure? How should I prepare? What does the equipment look like? How does the procedure work? How is the procedure
More informationLymphoma co existing with Tuberculosis granulomatous
Available online at www.worldscientificnews.com WSN 90 (2017) 265-270 EISSN 2392-2192 SHORT COMMUNICATION Lymphoma co existing with Tuberculosis granulomatous Madeeha Subhan 1, *, Waleed Sadiq 2 1 Ayub
More informationFDG PET/CT STAGING OF LUNG CANCER. Dr Shakher Ramdave
FDG PET/CT STAGING OF LUNG CANCER Dr Shakher Ramdave FDG PET/CT STAGING OF LUNG CANCER FDG PET/CT is used in all patients with lung cancer who are considered for curative treatment to exclude occult disease.
More informationL hyperfixation dans le suivi des lymphomes représente-t-elle toujours une maladie active?
L hyperfixation dans le suivi des lymphomes représente-t-elle toujours une maladie active? Thierry Vander Borght UCL Mont-Godinne, Belgique FDG-PET in Lymphoma: Mont-Godinne Experience 03/2000 10/2002:
More informationCase of the Day Chest
Case of the Day Chest Darin White MDCM FRCPC Department of Radiology, Mayo Clinic 76 th Annual Scientific Meeting Canadian Association of Radiologists Montreal, QC April 26, 2013 2013 MFMER slide-1 Disclosures
More informationSELF-ASSESSMENT MODULE REFERENCE SPR 2018 Oncologic Imaging Course Adrenal Tumors November 10, :00 12:10 p.m.
SELF-ASSESSMENT MODULE REFERENCE SPR 2018 Oncologic Imaging Course Adrenal Tumors November 10, 2018 10:00 12:10 p.m. Staging Susan E. Sharp, MD 1. In the International Neuroblastoma Risk Group Staging
More informationREVIEW. Distinguishing benign from malignant adrenal masses
Cancer Imaging (2003) 3, 102 110 DOI: 10.1102/1470-7330.2003.0006 CI REVIEW Distinguishing benign from malignant adrenal masses Isaac R Francis Professor of Radiology, Department of Radiology, University
More informationComputed Tomography of Normal Adrenal Glands in Indian Population
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 17, Issue 01 Ver. V January. (2018), PP 26-30 www.iosrjournals.org Computed Tomography of Normal Adrenal
More informationApproach to Pulmonary Nodules
Approach to Pulmonary Nodules Edwin Jackson, Jr., DO Assistant Professor-Clinical Director, James Early Detection Clinic Department of Internal Medicine Division of Pulmonary, Allergy, Critical Care and
More informationHemorrhoids: A Possible Cause of High FDG Uptake in the Rectum
Hemorrhoids: A Possible Cause of High FDG Uptake in the Rectum Yu-Yu Lu, Wan-Yu Lin Department of Nuclear Medicine, Taichung Veterans General Hospital, Taichung, Taiwan A 52-year-old man underwent 18 F-FDG
More informationHigh Tech Imaging Quick Reference Guide
High Tech Imaging Quick Reference Guide 1 High Tech Imaging Authorizations may now be requested through our secure provider portal, BlueAccess. Getting Started Step 1: Log into BlueAccess from www.bcbst.com
More informationCLINICAL PRESENTATION AND RADIOLOGY QUIZ QUESTION
Donald L. Renfrew, MD Radiology Associates of the Fox Valley, 333 N. Commercial Street, Suite 100, Neenah, WI 54956 4/30/2011 Radiology Quiz of the Week # 18 Page 1 CLINICAL PRESENTATION AND RADIOLOGY
More informationSolitary Contralateral Adrenal Metastases after Nephrectomy for Renal Cell Carcinoma
Original Report ISSN 1537-744X; DOI 10.1100/tsw.2004.39 Solitary Contralateral Adrenal after Nephrectomy for Renal Cell Carcinoma Nikolaos Antoniou, M.D. and Demetrios Karanastasis, M.D. General Hospital
More informationRole of CT imaging to evaluate solitary pulmonary nodule with extrapulmonary neoplasms
Original Research Article Role of CT imaging to evaluate solitary pulmonary nodule with extrapulmonary neoplasms Anand Vachhani 1, Shashvat Modia 1*, Varun Garasia 1, Deepak Bhimani 1, C. Raychaudhuri
More informationRadiation Exposure to Staff Using PET/CT Facility
Egyptian J. Nucl. Med., Vol. 8, No. 2, December 2013 1 Editorial Radiation Exposure to Staff Using PET/CT Facility Taalab, Kh; and Mohsen, Z Department of Nuclear Medicine, International Medical Center;
More informationAssessing the lung and mediastinum in cancer-is tissue the issue? George Santis
1 Assessing the lung and mediastinum in cancer-is tissue the issue? George Santis Optimal management of Cancer Histological diagnosis & accurate staging at presentation Molecular analysis of primary tumour
More informationNuclear medicine in oncology. 1. Diagnosis 2. Therapy
Nuclear medicine in oncology 1. Diagnosis 2. Therapy Diagnosis - Conventional methods - Nonspecific radiopharmaceuticals cumulating in tumours - Specific radiopharmaceuticals (receptor- and immunoscintigraphy)
More informationHEALTHFIRST 2011 RADIOLOGY PROGRAM CODE LIST
HEALTHFIRST 2011 RADIOLOGY PROGRAM CODE LIST Outpatient Radiology utilization call Carecore at 1-877-773-6964 Modality CPT CODE Description CT SCANS 70450 CT HEAD/BRAIN W/O CONTRAST CT SCANS 70460 CT HEAD/BRAIN
More informationNuclear pulmonology. Katalin Zámbó Department of Nuclear Medicine
Nuclear pulmonology Katalin Zámbó Department of Nuclear Medicine Imaging techniques Morphology Physiology Metabolism Molecules X-ray / CT MRI NM - SPECT/ PET MR spectroscopy fmri Ultrasound Hybrid imaging:
More informationStaging recurrent ovarian cancer with 18 FDG PET/CT
ONCOLOGY LETTERS 5: 593-597, 2013 Staging recurrent ovarian cancer with FDG PET/CT SANJA DRAGOSAVAC 1, SOPHIE DERCHAIN 2, NELSON M.G. CASERTA 3 and GUSTAVO DE SOUZA 2 1 DIMEN Medicina Nuclear and PET/CT
More informationC ancer cells require a great deal of sugar (glucose) for. PET/CT imaging: detection of choroidal melanoma SCIENTIFIC REPORT
265 SCIENTIFIC REPORT PET/CT imaging: detection of choroidal melanoma S Reddy, M Kurli, L B Tena, P T Finger... Aim: To determine the size of untreated choroidal melanomas resolved by whole body positron
More informationLung Cancer Screening in the Midwest of the US: When Histoplasmosis Complicates the Picture
Cronicon OPEN ACCESS EC PULMONOLOGY AND RESPIRATORY MEDICINE Case Report Lung Cancer Screening in the Midwest of the US: When Histoplasmosis Complicates the Picture Swan Lee 1 and Rolando Sanchez Sanchez
More informationWhat Radiologists do?
Multimodality Imaging in Oncology 2018 March 5 th 9th Diagnostic Imaging in Oncology What Radiologists do? Chikako Suzuki, MD, PhD Department of Diagnostic Radiology, KS Solna Department of Molecular Medicine
More informationCigna - Prior Authorization Procedure List: Radiology & Cardiology
Cigna - Prior Authorization Procedure List: Radiology & Cardiology Product Category CPT Code CPT Code Description Radiology MR 70336 MRI Temporomandibular Joint(s), (TMJ) Radiology CT 70450 CT Head or
More informationPET imaging of cancer metabolism is commonly performed with F18
PCRI Insights, August 2012, Vol. 15: No. 3 Carbon-11-Acetate PET/CT Imaging in Prostate Cancer Fabio Almeida, M.D. Medical Director, Arizona Molecular Imaging Center - Phoenix PET imaging of cancer metabolism
More informationThyroid Cancer: Imaging Techniques (Nuclear Medicine)
Thyroid Cancer: Imaging Techniques (Nuclear Medicine) Andrei Iagaru, MD MIPS Molecular Imaging Program at Stanford Stanford University School of Medicine Department of Radiology Introduction Ø There are
More information